ProfileGDS5678 / 1457069_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 67% 70% 70% 69% 69% 66% 69% 67% 67% 68% 73% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2188869
GSM967853U87-EV human glioblastoma xenograft - Control 24.0907467
GSM967854U87-EV human glioblastoma xenograft - Control 34.3298470
GSM967855U87-EV human glioblastoma xenograft - Control 44.4661970
GSM967856U87-EV human glioblastoma xenograft - Control 54.2000269
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2819969
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0608566
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2427569
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0888767
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0740767
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1444968
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7386273
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1836268
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1468968